Since pembrolizumab is only approved for the treatment of HNSCC in patients with CPS ≥ 1, all patients with CPS < 1 or unknown PD‐L1 expression were treated with nivolumab. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.